CTLA4 anticorps (PE)

N° du produit ABIN2663048

Cet anticorps anti-CTLA4 Monoclonal Souris conjugué à PE (Clone WKH203) (ABIN2663048) détecte spécifiquement CTLA4 dans FACS. L’anticorps est réactif avec des échantillons de Rat.

Aperçu rapide pour CTLA4 anticorps (PE) (ABIN2663048)

Antigène: CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Reactivité: Rat

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CTLA4 est conjugé à/à la PE

Application: Flow Cytometry (FACS)

Clone: WKH203

Détail du produit anti-CTLA4 anticorps (PE)

Purification: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotype: IgG1 kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur CTLA4

Antigène: CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Autre désignation: CD152

Sujet: CD152 is a 33 kD member of the immunoglobulin superfamily also known as CTLA-4 or Ly-56. It is expressed on activated T and B lymphocytes. CD152 is similar to CD28 in amino acid sequence, structure, and genomic organization and these two receptors share common B7 family counter-receptors (B7-1, B7-2). Whereas CD28 delivers a costimulatory signal in T cell activation, CTLA-4 negatively regulates cell-mediated immune responses. CD152 is thought to play a role in the induction and maintenance of immunological tolerance, as well as the development of protective immunity and thymocyte regulation.

Pathways: Cancer Immune Checkpoints